Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
Amoxicillin
Athlone Laboratories Ltd
J01CA; J01CA04
Amoxicillin
250 mg/5ml
Powder for oral suspension
Product subject to prescription which may not be renewed (A)
Penicillins with extended spectrum; amoxicillin
Marketed
1988-09-27
0011 PRAC CCRF23052 PACKAGE LEAFLET: INFORMATION FOR THE USER ORAMOX 125MG / 5ML POWDER FOR ORAL SUSPENSION ORAMOX 250MG / 5ML POWDER FOR ORAL SUSPENSION Amoxicillin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you (or for your child) only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Oramox is and what it is used for 2. What you need to know before you take Oramox 3. How to take Oramox 4. Possible side effects 5. How to store Oramox 6. Contents of the pack and other information 1. WHAT ORAMOX IS AND WHAT IT IS USED FOR WHAT ORAMOX IS Oramox is an antibiotic. The active ingredient is amoxicillin trihydrate. This belongs to a group of medicines called ‘penicillins’. WHAT ORAMOX IS USED FOR Oramox is used to treat infections caused by bacteria in different parts of the body. Oramox may also be used in combination with other medicines to treat stomach ulcers. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ORAMOX DO NOT TAKE ORAMOX • if you are allergic to amoxicillin, penicillin or any of the other ingredients of this medicine (listed in section 6) • if you have ever had an allergic reaction to any antibiotic. This can include a skin rash or swelling of the face or throat. Do not take Oramox if any of the above apply. If you are not sure, talk to your doctor or pharmacist before taking Oramox WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Oramox if you: • have glandular fever (fever, sore throat, swollen glands and extreme tiredness) • have kidney problems • are not urinating regularly If you are not sure if Pročitajte cijeli dokument
Health Products Regulatory Authority 16 March 2023 CRN00DGQH Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Oramox 250 mg/5 ml Powder for Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml of reconstituted suspension contains amoxicillin trihydrate, equivalent to 250 mg of Amoxicillin. Excipient(s) with known effect: Each 5ml dose contains 2.7 g of sucrose, 6.47 mg of sodium and 4.82 mg of sodium benzoate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for oral suspension A pale yellow crystalline powder for oral suspension with the odour and flavour of lemon 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oramox is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): Acute bacterial sinusitis Acute otitis media Acute streptococcal tonsillitis and pharyngitis Acute exacerbations of chronic bronchitis Community acquired pneumonia Acute cystitis Asymptomatic bacteriuria in pregnancy Acute pyelonephritis Typhoid and paratyphoid fever Dental abscess with spreading cellulitis Prosthetic joint infections _Helicobacter pylori _eradication Lyme disease Oramox is also indicated for the prophylaxis of endocarditis Consideration should be given to official guidance on the appropriate use of antibacterial agents 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose of Oramox that is selected to treat an individual infection should take into account: The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4) The severity and the site of the infection The age, weight and renal function of the patient; as shown below Health Products Regulatory Authority 16 March 2023 CRN00DGQH Page 2 of 14 The duration of therapy should be determined by the type of infection and the response of the patient, and should generally be as short as possible. Some infections require longer periods of tr Pročitajte cijeli dokument